Advanced or Metastatic Solid Tumors Clinical Trial
Official title:
A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors
Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of
daily oral administration of metatinib tromethamine in subjects with solid tumors;
Investigate the influence of food on pharmacokinetic parameters.
Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral
administration of metatinib tromethamine in subjects with solid tumors; To observe
preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive
biomarkers at MTD.
Status | Completed |
Enrollment | 18 |
Est. completion date | December 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 74 Years |
Eligibility |
Inclusion Criteria: - Weight: male weight = 45 kg; female weight = 40 kg, body mass index (BMI) between 18~24 kg/m^2, including the boundary values; - The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no known therapies to prolong survival; - Not treated with standard therapeutical regime currently, or has progressed or relapsed after standard treatment; - Time from last cytotoxic chemotherapy (including investigational cytotoxic agents) or biologic agents (immune modulators, cytokines) = 4 weeks, or nitrosoureas or mitomycin C = 6 weeks. If having received an antibody anti-tumor biological product, at least 8-week washout period is required; - At least 4 weeks after surgery, and the wound must be healed completely; - If subject has chemotherapy-induced toxicity, the adverse events must be recovered to = grade 1 (NCI-CTC version 4.0) except for alopecia; - ECOG performance status of 0-2; - Expected survival time is more than three months; - The subject has organ and marrow function as follows: 1. absolute neutrophil count (ANC) = 1.5 x 10^9/L, 2. platelets = 80 x 10^9/L, 3. hemoglobin = 90 g/L (blood transfusion is allowed), 4. total bilirubin = 2 x ULN (<3 x ULN with liver metastases), 5. serum creatinine = 150 µmol/L or calculated creatinine clearance = 60 mL/min, 6. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN (<5 x ULN with liver metastases), 7. uric acid <500 µmol/L, 8. proteinuria = 2 + or = 2g / 24h; - The subject is capable of understanding and complying with the protocol and has signed the informed consent document; Exclusion Criteria: - The subject is known to be positive for the human immunodeficiency virus (HIV); - The subject is known to be positive for hepatitis B surface antigen or hepatitis C; - Previous participation in other clinical trials within three months before study; - Concomitant chemotherapy, hormone therapy, immunotherapy program or radiotherapy; - The subject has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; - The subject has psychiatric illness/social situations that would limit compliance with study requirements; - The subject has brain metastases; - Imaging study showed involvement of major blood vessels or nerves by tumor; - Uncontrollable hypertension (referring to systolic blood pressure> 150 mmHg and / or diastolic blood pressure> 100 mmHg after treatment) or LVEF <50%; - Patient with disease history of bleeding or thromboembolic events occurred within the past six months and need for preventive anticoagulant therapy; - Patient needs surgery within 28 days, or is expected to require surgery within 28 days after the last dose administration; - Significant abnormality in the important organs, such as heart, lung, liver, kidney; - Has third lacunar effusion with difficulty to control; - The subject is pregnant or breastfeeding; - Sexually active subjects (male and female) refuse to use medically acceptable methods of contraception during the course of the study and for 1 month following discontinuation of study drug. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | West China Hospital, Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Simcere Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting Toxicity (DLT) | up to day 32 | Yes | |
Primary | Maximum Tolerated Dose (MTD) | up to day 32 | Yes | |
Secondary | Cmax | d1?d2?d3?d8?d15?d22?d29?d30?d31 | No | |
Secondary | AUC | d1?d2?d3?d8?d15?d22?d29?d30?d31 | No | |
Secondary | Objective response rate (ORR) | week 4, week 10, week 16 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05017012 -
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
|
Phase 1 | |
Completed |
NCT02261532 -
A Phase I Study of TAS-102 in Solid Tumors
|
Phase 1 | |
Completed |
NCT00748553 -
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03248843 -
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04003623 -
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
|
Phase 2 | |
Terminated |
NCT05496595 -
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01928394 -
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01506934 -
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03730337 -
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04586270 -
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
|
Phase 1 | |
Recruiting |
NCT06248411 -
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06389526 -
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03665285 -
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05957081 -
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
|
Phase 1 | |
Active, not recruiting |
NCT03316638 -
A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01355302 -
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01014429 -
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06074497 -
A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04866134 -
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 |